Nurix Therapeutics Inc (NRIX) FinancialsNRIXFinancialNurix Therapeutics Inc

Evaluating the bottom line, Nurix Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1041.73%, while the net margin is -990.10%. These profitability ratios, combined with a Return on Equity (ROE) of -80.30%, provide a clear picture of how effectively NRIX converts its operational activities into shareholder value.

In the context of the broader market, NRIX competes directly with industry leaders such as BCRX and PGEN. With a market capitalization of $2.79B, it holds a leading position in the sector. When comparing efficiency, NRIX's gross margin of 100.00% stands against BCRX's 98.24% and PGEN's 94.90%. Such benchmarking helps identify whether Nurix Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Nurix has shown fluctuating revenue, with Q2 2026 revenue at 9,043,000 USD, but it has a gross margin of 100%, indicating strong profitability on sales. However, net income remains negative, with a significant loss of -89,535,000 USD in Q2 2026.